JPMorgan ditches call to buy Chinese stocks, citing 'Tariff War 2.0' risk

By Harry Robertson

LONDON (Reuters) - JPMorgan has ditched its buy recommendation on Chinese stocks, warning of the risk of a second tariff war after November's U.S. election and citing worries about the country's growth.

The bank downgraded China to "neutral" from "overweight" in a note on Wednesday and recommended investors add to bets on countries such as India, Mexico and Saudi Arabia instead.

WHY IT’S IMPORTANT

China's economy is stumbling - by its standards - and the country is struggling to attract global investors, who have moved heavily into other emerging markets such as India.

KEY QUOTE

"China equities could see heightened volatility around the upcoming U.S. elections," JPMorgan analysts, including Pedro Martins, said in the note.

"The impact of a potential 'Tariff War 2.0' (with tariffs increasing from 20% to 60%) could be more significant than the first tariff war."

CONTEXT

China's CSI 300 stock index has fallen more than 40% since hitting a record high in 2021, with the country increasingly in economic conflict with the United States and suffering from a property crisis.

Survey data over the weekend showed China's manufacturing activity sank to a six-month low in August. And weaker-than-expected second-quarter growth called into question China's ability to hit its 5% GDP target this year.

BY THE NUMBERS

JPMorgan said U.S. tariffs of 60% on Chinese products, as Republican presidential candidate Donald Trump has suggested, may reduce China's GDP growth by two percentage points from its current forecast of 4% year-on-year in 2025, excluding any policy responses.

The bank said it now expects full-year growth in 2024 to come in at 4.6%, below the 5% target.

WHAT'S NEXT



Investors will scrutinise Chinese economic data and hope for a bigger stimulus response from Beijing than the existing reductions to borrowing rates. Inflation and trade balance figures are due next week.

GRAPHIC

Source: Investing.com

Останні публікації
Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy
24.01.2025 - 18:00
Crypto markets lose steam after Trump's first policy move
24.01.2025 - 18:00
Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson
24.01.2025 - 18:00
British American Tobacco, Altria shares rise after menthol ban proposal dropped
24.01.2025 - 18:00
Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%
24.01.2025 - 18:00
Commerzbank says no talks with UniCredit until specific proposal made
24.01.2025 - 18:00
Venture Global aims for $64 billion valuation at debut in test for energy IPOs
24.01.2025 - 18:00
Intuitive Machines stock surges on NASA contract award
24.01.2025 - 18:00
International Paper's $7.2 billion acquisition of DS Smith gets EU approval
24.01.2025 - 18:00
Short-term stock optimism soars among retail investors, AAII survey shows
24.01.2025 - 18:00
Venture Global shares likely to open up to 6% above IPO price
24.01.2025 - 18:00
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
24.01.2025 - 18:00
BMW joins Chinese EV makers in filing EU court challenge to tariffs
24.01.2025 - 18:00
Turkey stocks lower at close of trade; BIST 100 down 0.08%
24.01.2025 - 18:00
Diageo stock jumps on possible Guinness sale
24.01.2025 - 18:00

© Analytic DC. All Rights Reserved.

new
Аналіз ринку Як вплине завтра звіт NFP на курс долара США?